Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Modified Shenling Baizhu Powder is a Traditional Chinese Medicine (TCM) herbal formula derived from the classic Shenling Baizhu San. It is being evaluated as an adjunctive therapy for the treatment of persistent allergic asthma, specifically in patients presenting with the TCM syndrome of spleen deficiency and dampness accumulation. The formula typically contains a combination of herbs such as Panax ginseng, Poria cocos, and Atractylodes macrocephala, which are intended to strengthen the spleen, transform dampness, and improve respiratory function. In clinical trials led by the Henan University of Chinese Medicine, it is used alongside standard-of-care inhaled corticosteroids and long-acting beta-agonists (Budesonide/Formoterol) to improve asthma control and quality of life.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Modified Shenling Baizhu Powder.